Anti-Human CD30 Ligand (Clone 116614)
| Code | Size | Price |
|---|
| LEI-C1379-25ug | 25 ug | £375.00 |
Quantity:
| LEI-C1379-100ug | 100 ug | £659.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG2b
Antibody Clonality: Monoclonal
Antibody Clone: 116614
Regulatory Status: RUO
Target Species: Human
Applications:
- Flow Cytometry
- Neutralisation
Shipping:
Ambient
Storage:
The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.
Further Information
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This monoclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Formulation:
This monoclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Immunogen:
Purified Recombinant Human CD30 Ligand (Accession # P32971)
Long Description:
The CD30 ligand is a type II transmembrane glycoprotein of the tumor necrosis factor ligand superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. Recombinant CD30L has been shown to co-stimulate T cells and to act as a mitogen for Hodgkin's disease derived cell lines. The receptor for CD30L, CD30/ TNFRSF8/CD153, is a type I cytokine receptor that is highly expressed by activated T cells, Hodgkin and Reed- Sternberg (H-RS) cells, and anaplastic large cell lymphoma cells. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis.
Target:
CD30 Ligand
References
1. Croager, EJ. et al. (1997) Biochim. Biophys. Acta. 1353:2312. Gruss, HJ. et al. (1994) Blood 83:15213. Wendtner, CM. et al. (1995) Cancer Res. 55:41574. Fischer, M. et al. (2006) J. Clin. Invest. 116:27485. Blazar, BR. et al. (2004) J. Immunol. 173:2933
Related Products
| Product Name | Product Code | Supplier | Anti-Human CD30 Ligand (TNFSF8) | LEI-C1456 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human CD30 Ligand-Biotin | LEI-C1488 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse CD30 Ligand - Biotin | LEI-C1521 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||